ArticleLipids in health and disease2026
Plasma lipoprotein (a) and long-term all-cause mortality in myocardial infarction survivors: a cohort study.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElevated concentrations of lipoprotein (a) [Lp(a)] are a well-established risk factor for the development of coronary artery diseases and acute myocardial infarction (AMI). The objective of the present study was to analyze the association between plasma concentrations of Lp(a) and long-term all-cause mortality among individuals with a history of hospitalized AMI.
methodsThe analysis was based on data from 617 patients with a history of AMI recruited by the Augsburg Myocardial Infarction Registry and examined in a follow-up visit within the scope of the KORA Family Heart Study in 1996 and 1997 (median time between AMI and follow-up examination: 6.2 years). In addition, 545 siblings of the patients were included in the study and underwent examination. The examination included venous blood sampling and a patient interview. Plasma concentrations of Lp(a) were measured using a latex-enhanced immunoassay. Information on vital status was obtained in November 2025 in a comprehensive mortality follow-up [median follow-up time: 18.2 years (IQR: 10.8-27.7)]. Follow-up time was calculated from examination date to date of death or censoring. Kaplan-Meier curves were used to display estimated survival probability of Lp(a) high (≥ 50 mg/dL) and low (< 50 mg/dL) group. Multivariable adjusted Cox regression models with restricted cubic splines were used to analyze the association between Lp(a) concentrations and long-term all-cause mortality after AMI.
resultsKaplan-Meier curves and log rank test (p value: 0.273) demonstrated no differences in long-term all-cause mortality between the high and low Lp(a) group. The multivariable adjusted Cox regression confirmed the absence of a significant association between Lp(a) concentrations and total mortality (HR for the high Lp(a) group: 1.04, 95%CI: 0.84-1.28, p value: 0.734). Several sensitivity analyses, including a mixed model on a sample including siblings of the AMI patients (HR for the high Lp(a) group: 1.09) and a more thoroughly adjusted model including additional potential confounders confirmed the results of the main model.
conclusionsIn this study, no association between elevated Lp(a) and long-term mortality was detected. Due to the observational character of the study, no conclusions about treatment of patients with elevated Lp(a) can be made and results must be regarded as exploratory and hypothesis generating.
Indexed as
Identifiers
43026572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.